Literature DB >> 23338015

Antimicrobial susceptibilities of Clostridium difficile isolated in Japan.

Hiroyuki Kunishima1, Junichi Chiba, Michiko Saito, Yoshihiro Honda, Mitsuo Kaku.   

Abstract

Clostridium difficile is a common causative organism of antimicrobial-associated diarrhea and is often responsible for nosocomial infection. C. difficile infection has traditionally been treated with metronidazole (MNZ) or vancomycin (VCM); however, MNZ-resistant strains have reported in some countries. In this study the broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 15 drugs against 157 clinical isolates of C. difficile in Japan. All C. difficile isolates tested were susceptible to MNZ; MIC50 was 0.25 μg/ml, MIC90 was 0.5 μg/ml, and MIC range was 0.06-1 μg/ml. C. difficile isolates were also susceptible to VCM; MIC50 was 0.5 μg/ml, MIC90 was 1 μg/ml, and MIC range was 0.12-2 μg/ml. Susceptibility to teicoplanin was also similar: MIC50 was 0.12 μg/ml, MIC90 was 0.12 μg/ml, and MIC range was 0.03-0.25 μg/ml. The susceptibility of C. difficile isolates must be monitored continuously because a strain with reduced susceptibility to MNZ or VCM might emerge in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338015     DOI: 10.1007/s10156-013-0553-5

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  2 in total

1.  Bi-functionalization of a calcium phosphate-coated titanium surface with slow-release simvastatin and metronidazole to provide antibacterial activities and pro-osteodifferentiation capabilities.

Authors:  Yunsong Liu; Xiao Zhang; Yang Liu; Xiaoxiao Jin; Cong Fan; Hongqiang Ye; Meng'en Ou; Longwei Lv; Gang Wu; Yongsheng Zhou
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 2.  The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review.

Authors:  Thomas V Riley; Tomomi Kimura
Journal:  Infect Dis Ther       Date:  2018-02-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.